HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 280, Issue 3, 1797-1807, January 21, 2005

This Article Full Text Full Text (PDF) All Versions of this Article: 280/3/1797    most recent M408270200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shimizu, N. Articles by Gardella, T. J. Search for Related Content PubMed PubMed Citation Articles by Shimizu, N. Articles by Gardella, T. J. Social Bookmarking                      What's this?

Novel Parathyroid Hormone (PTH) Antagonists That Bind to the Juxtamembrane Portion of the PTH/PTH-related Protein Receptor^*

Naoto Shimizu, Thomas Dean, Janet C. Tsang, Ashok Khatri, John T Potts, Jr, and Thomas J. Gardella

From the Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Current antagonists for the parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor (PTHR) are N-terminally truncated or N-terminally modified analogs of PTH(1–34) or PTHrP(1–34) and are thought to bind predominantly to the N-terminal extracellular (N) domain of the receptor. We hypothesized that ligands that bind only to PTHR region comprised of the extracellular loops and seven transmembrane helices (the juxtamembrane or J domain) could also antagonize the PTHR. To test this, we started with the J domain-selective agonists [Gln¹⁰,Ala¹²,Har¹¹,Trp¹⁴,Arg¹⁹ (M)]PTH(1–21), [M]PTH(1–15), and [M]PTH(1–14), and introduced substitutions at positions 1–3 that were predicted to dissociate PTHR binding and cAMP signaling activities. Strong dissociation was observed with the tri-residue sequence diethylglycine (Deg)¹-para-benzoyl-L-phenylalanine (Bpa)²-Deg³. In HKRK-B7 cells, which express the cloned human PTHR, [Deg^1,3,Bpa²,M]PTH(1–21), [Deg^1,3,Bpa²,M]PTH(1–15), and [Deg^1,3,Bpa²,M]PTH(1–14) fully inhibited (IC₅₀s = 100–700 nM) the binding of ¹²⁵I-[-aminoisobutyric acid^1,3,M]PTH(1–15) and were severely defective for stimulating cAMP accumulation. In ROS 17/2.8 cells, which express the native rat PTHR, [Deg^1,3,Bpa²,M]PTH(1–21) and [Deg^1,3,Bpa²,M]PTH(1–15) antagonized the cAMP-agonist action of PTH(1–34), as did PTHrP(5–36) (IC₅₀s = 0.7 µM, 2.6 µM, and 36 nM, respectively). In COS-7 cells expressing PTHR-delNt, which lacks the N domain of the receptor, [Deg^1,3,Bpa², M]PTH(1–21) and [Deg^1,3,Bpa²,M]PTH(1–15) inhibited the agonist actions of [-aminoisobutyric acid^1,3]PTH(1–34) and [M]PTH(1–14) (IC₅₀s 1 µM), whereas PTHrP(5–36) failed to inhibit. [Deg^1,3,Bpa²,M]PTH(1–14) inhibited the constitutive cAMP-signaling activity of PTHR-tether-PTH(1–9), in which the PTH(1–9) sequence is covalently linked to the PTHR J domain, as well as that of PTHR_camH223R. Thus, the J-domain-selective N-terminal PTH fragment analogs can function as antagonists as well as inverse agonists for the PTHR. The new ligands described should be useful for further studies of the ligand binding and activation mechanisms that operate in the critical PTHR J domain.

Received for publication, July 21, 2004 , and in revised form, November 1, 2004.

^* This work was supported by Grant DK-11794 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 617-726-3966; Fax: 617-726-7543; E-mail: gardella{at}helix.mgh.harvard.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. J. Gardella Mimetic Ligands for the PTHR1: Approaches, Developments, and Considerations IBMS BoneKEy, February 1, 2009; 6(2): 71 - 85. [Abstract] [Full Text] [PDF]

				P Iglesias and J J Diez Current treatments in the management of patients with primary hyperparathyroidism Postgrad. Med. J., January 1, 2009; 85(999): 15 - 23. [Abstract] [Full Text] [PDF]

				I. Assil-Kishawi, T. A. Samra, D. F. Mierke, and A. B. Abou-Samra Residue 17 of Sauvagine Cross-links to the First Transmembrane Domain of Corticotropin-releasing Factor Receptor 1 (CRFR1) J. Biol. Chem., December 19, 2008; 283(51): 35644 - 35651. [Abstract] [Full Text] [PDF]

				M. Okazaki, S. Ferrandon, J.-P. Vilardaga, M. L. Bouxsein, J. T. Potts Jr, and T. J. Gardella Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation PNAS, October 28, 2008; 105(43): 16525 - 16530. [Abstract] [Full Text] [PDF]

				S. R. J. Hoare, B. A. Fleck, R. S. Gross, P. D. Crowe, J. P. Williams, and D. E. Grigoriadis Allosteric Ligands for the Corticotropin Releasing Factor Type 1 Receptor Modulate Conformational States Involved in Receptor Activation Mol. Pharmacol., May 1, 2008; 73(5): 1371 - 1380. [Abstract] [Full Text] [PDF]

				T. Dean, J.-P. Vilardaga, J. T. Potts Jr., and T. J. Gardella Altered Selectivity of Parathyroid Hormone (PTH) and PTH-Related Protein (PTHrP) for Distinct Conformations of the PTH/PTHrP Receptor Mol. Endocrinol., January 1, 2008; 22(1): 156 - 166. [Abstract] [Full Text] [PDF]

				P. H. Carter, R.-Q. Liu, W. R. Foster, J. A. Tamasi, A. J. Tebben, M. Favata, A. Staal, M. E. Cvijic, M. H. French, V. Dell, et al. Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probe PNAS, April 17, 2007; 104(16): 6846 - 6851. [Abstract] [Full Text] [PDF]

				T. Dean, A. Khatri, Z. Potetinova, G. E. Willick, and T. J. Gardella Role of Amino Acid Side Chains in Region 17-31 of Parathyroid Hormone (PTH) in Binding to the PTH Receptor J. Biol. Chem., October 27, 2006; 281(43): 32485 - 32495. [Abstract] [Full Text] [PDF]

				T. Dean, A. Linglart, M. J. Mahon, M. Bastepe, H. Juppner, J. T. Potts Jr., and T. J. Gardella Mechanisms of Ligand Binding to the Parathyroid Hormone (PTH)/PTH-Related Protein Receptor: Selectivity of a Modified PTH(1-15) Radioligand for G{alpha}S-Coupled Receptor Conformations Mol. Endocrinol., April 1, 2006; 20(4): 931 - 943. [Abstract] [Full Text] [PDF]

				E. Seeman and G. J. Strewler Clinical and Basic Research Papers - January 2005 Selections IBMS BoneKEy, February 1, 2005; 2(2): 1 - 6. [Full Text] [PDF]